Roche Launches Tender Offer to Acquire All Shares of 89bio, Inc. at $14.50 Each in Cash, Along with a Non-Tradeable Contingent Value Right Worth Up to $6.00 per Share in Cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 01 2025
0mins
Should l Buy ?
Source: Newsfilter
Roche's Tender Offer for 89bio: Roche has initiated a tender offer to acquire all outstanding shares of 89bio, Inc. at $14.50 per share, along with potential milestone payments totaling up to $6.00 per share, as part of a merger agreement announced on September 17, 2025.
Conditions and Timeline: The tender offer will expire on October 29, 2025, and is subject to customary closing conditions, including regulatory approvals and a majority of shares being tendered. If successful, any remaining shares will be acquired in a second-step merger at the same price.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
